

30th April 2021

BSE LIMITED Market Operations Dept., P J Towers Dalal Street, Mumbai – 400001 Scrip Code: BSE – AJANTPHARM 532331	National Stock Exchange of India, Exchange Plaza, 5 th Floor, Plot no. C/1, G Block, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051 Scrip Code: NSE AJANTPHARM EQ
--	--

Dear Sir/ Madam,

Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This is to inform you that Ajanta Pharma Limited has subscribed to partnership interest in ABCD Technologies LLP (to be renamed as IndoHealth Services LLP).

The disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Clause A(1) of Part A, Schedule III of the aforesaid regulations, is attached as per “**Annexure A**”.

This is for your information and dissemination.

Yours faithfully,

GAURANG SHAH

VP – Legal & Company Secretary

Encl: Annexure A



Annexure A

Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 under Clause A(1) of Part A, Schedule III of the aforesaid regulations on subscription of partnership interest in ABCD Technologies LLP (to be renamed as IndoHealth Services LLP) by the Company.

a) Name of the target entity, details in brief such as size, turnover etc.:	<p><i>i) Name of the Target entity:</i></p> <p>ABCD Technologies LLP (to be renamed as IndoHealth Services LLP), herein after referred to as the Target entity.</p> <p><i>ii) Details of Target entity:</i></p> <p>The Target entity is a limited liability partnership ('LLP') that has various partners. The Target entity will, through its investment entities, engage in the objective of digitizing healthcare infrastructure in India.</p>
b) Whether the acquisition would fall within related party transaction(s) and whether the promoter/promoter group/group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "Arms-length";	No.
c) Industry to which the entity being acquired belongs;	Healthcare services.
d) Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity;	Initiative with an objective to facilitate, enable and promote efficiency and Good Distribution Practices ('GDP') including digitizing healthcare infrastructure in India, <i>inter-alia</i> , in support of the National Digital Health Mission of Government of India ('Business').
e) Brief details of any governmental or regulatory approvals required for the acquisition;	None.
f) Indicative time period for completion of the acquisition;	To be completed on or before 30 th April 2021.



g) Nature of consideration – whether cash consideration or share swap and details of the same;	Cash infusion as capital contribution.
h) Cost of acquisition or the price at which the shares are acquired;	INR 25 crores.
i) Percentage of shareholding / control acquired and/or number of shares acquired;	4.03% share of profit/ loss in the Target entity.
j) Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	<p>The Target entity has been incorporated on 10th February 2021.</p> <p>The Target entity through its investments in DigiHealth Technologies LLP, Pharmarack Technologies Private Limited, Trikaal Mediinfotech Private Limited and AIOCD Pharmasofttech Awacs Private Limited, aims to achieve the objectives as per clause (d) above.</p>